Firsekibart is named as an intervention in 4 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Chinese SLE Treatment And Research Group (1). The most-studied condition is Lupus Erythematosus, Systemic.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
NCT07191444 · ClinicalTrials.gov ↗ · Still's Disease, Adult-Onset
|
Observational | Recruiting | Ruijin Hospital | China |
|
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
NCT07686770 · ClinicalTrials.gov ↗ · Kawasaki Disease
|
Phase 2/3 | Not yet open | Children's Hospital of Fudan University | China |
|
24-Week Recurrence Rate of Gout Following Firsekibart Treatment
NCT07625514 · ClinicalTrials.gov ↗ · Gout Flare
|
Not applicable | Not yet open | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus
NCT07381465 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic
|
Phase 4 | Active, closed | Chinese SLE Treatment And Research Group | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Chinese SLE Treatment And Research Group | 1 |
| Children's Hospital of Fudan University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Ruijin Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Firsekibart as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Chinese SLE Treatment And Research Group (1), Children's Hospital of Fudan University (1), Second Affiliated Hospital, Zhejiang University, School of Medicine (1) and Ruijin Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Firsekibart works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Firsekibart works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Firsekibart (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.